Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Score, Valuation & Financial Research
Anbio Biotechnology Class A Ordinary Shares is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 48/100.
Quick answer for NNNN
Anbio Biotechnology Class A Ordinary Shares currently has a Wall Street Score of 48/100. The stored market price is $6.11. Its financial score is 32/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What Anbio Biotechnology Class A Ordinary Shares does
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
NNNN financial snapshot
- Wall Street Score:
- 48/100
- Current price:
- $6.11
- Market capitalization:
- $268.2M
- Revenue:
- $14.3M
- Net income:
- $7.2M
- Free cash flow:
- $-6.7M
- Cash:
- $7.8M
- Total debt:
- $0
- EPS:
- 0.16
- P/E ratio:
- 38.2x
- Financial score:
- 32/100
- Valuation score:
- 10/100
- Revenue score:
- 53/100
What stands out
- Reported year-over-year revenue growth is +0.7%.
- Free cash flow is $-6.7M, showing cash burn in the current stored period.
- The balance sheet shows $7.8M of cash versus $0 of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NNNN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.